AstraZeneca’s (AZN) fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older. Breztri is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist medicines with a long-acting muscarinic antagonist, LAMA. Breztri was approved in the US in 2020 to treat adults with chronic obstructive pulmonary disease, COPD, and was prescribed to more than 6.8 million patients globally in 2025.1,2
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Novartis (NVS) CEO Warns Trump Drug Pricing Policy Could Hit Global Access as Earnings Slip
- AstraZeneca’s Breztri Aerosphere approved in U.S. for asthma
- AstraZeneca Wins First U.S. Asthma Approval for Triple-Inhaler Breztri
- AstraZeneca Stock (AZN) Flattens Despite Green Light for Injector Pen to Stop “Killer” Lupus
- AstraZeneca’s Saphnelo has been approved in the U.S.